Peg-Ifn Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471AM1)(COMPLETED) - Full Text View

Sponsored by:	Schering-Plough
Information provided by:	Schering-Plough
ClinicalTrials.gov Identifier:	NCT00081770

Purpose

The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PEG-Intron 1.5 µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2) PEG-Intron 1µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3) PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day.

Condition	Intervention	Phase
Hepatitis C, Chronic	Biological: peginterferon alfa-2b (SCH 54031) Drug: ribavirin (SCH 18908) Biological: peginterferon alfa-2a Drug: ribavirin	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title:	Comparison of PEG-Intron 1.5µg/kg/wk Plus REBETOL vs PEG-Intron 1µg/kg/wk Plus REBETOL vs PEGASYS 180µg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1

Resource links provided by NLM:

MedlinePlus related topics: Hepatitis Hepatitis C

Drug Information available for: Ribavirin Interferon alfa-2b Peginterferon Alfa-2a Peginterferon Alfa-2b

U.S. FDA Resources

Further study details as provided by Schering-Plough:

Primary Outcome Measures:

Proportion of subjects with a sustained virologic response (SVR) at 24 weeks post-treatment. Co-primary treatment comparisons include: Arm 1 (PegIntron 1.5/R) vs Arm 2 (PegIntron 1.0/R), Arm 1 vs Arm 3 (PEGASYS/COPEGUS). [ Time Frame: 48-week treatment; 24-week follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Comparison of SVR rates of Arm2 vs Arm 3; SVR for African Americans vs non-African Americans; SVR by baseline viral load; virologic response (VR) at end of treatment; VR at Treatment Week 24 (TW24); VR at TW12; relapse rate. [ Time Frame: 48-week treatment; 24-week follow-up ] [ Designated as safety issue: No ]

Estimated Enrollment:	2880
Study Start Date:	March 2004
Study Completion Date:	November 2007

Arms	Assigned Interventions
PegIntron 1.5 ug/kg/wk plus REBETOL: Experimental PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/wk in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up	Biological: peginterferon alfa-2b (SCH 54031) 1.5 ug/kg/wk SC for 48 weeks Drug: ribavirin (SCH 18908) weight based dose 800-1400 mg/day PO for 48 weeks
PegIntron 1.0 ug/kg/wk plus REBETOL: Experimental PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/wk in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up	Biological: peginterferon alfa-2b (SCH 54031) 1.0 ug/kg/wk SC for 48 weeks Drug: ribavirin (SCH 18908) weight based dose 800-1400 mg/day PO for 48 weeks
PEGASYS 180 ug/wk Plus COPEGUS: Active Comparator PEGASYS (peginterferon alfa-2a) 180 ug/wk plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up	Biological: peginterferon alfa-2a 180 ug/wk SC administered for 48 weeks Drug: ribavirin 1000-1200 mg/day PO for 48 weeks

Detailed Description:

PEG-Intron Dose:

Screening 2 Weight 40-50 kg Volume to Inject (mL)0.22; Screening 2 Weight 51-60 kg Volume to Inject (mL)0.28; Screening 2 Weight 61-75 kg Volume to Inject (mL)0.33; Screening 2 Weight 76-85 kg Volume to Inject (mL)0.41; Screening 2 Weight 86-104 kg Volume to Inject (mL)0.48; Screening 2 Weight 105-125 kg Volume to Inject (mL)0.58 from two vials

REBETOL Dosage (for Use With PEG-INTRON):

Screening 2 Weight 40-60 kg Daily Dose 800mg; Screening 2 Weight >65-85 kg Daily Dose 1000mg; Screening 2 Weight >85-105 kg Daily Dose 1200mg; Screening 2 Weight >105-125 kg Daily Dose 1400mg

The PEGASYS dose of 1 mL (180 µg) will be administered once weekly subcutaneously on the same day of the week

COPEGUS Dosage (for Use With PEGASYS):

Screening 2 Weight <75kg Daily Dose 1000mg; Screening 2 Weight > or = 75kg Daily Dose 1200mg

NOTE: Double Blind for PEG-Intron; Open Label for REBETOL, PEGASYS and COPEGUS

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:

Previously untreated adults with chronic hepatitis C (HCV RNA qPCR plasma positive)
Individuals with HCV genotype 1 (mixed 1a/1b is acceptable)
Compensated liver disease
No significant co-existing psychiatric disease
Historic liver biopsy slides available
Adults aged 18-70
Individuals weighing 88-275 pounds (40-125 kg)
Free from substance abuse for past 2 years
Those suffering from diabetes and/or hypertension must have normal eye exams and retinal photographs (these will be done as part of the study before hepatitis C treatment is given)
Patients and partners of patients willing to use adequate contraception during the course of the study
Hematology laboratory results of:
- Hemoglobin (HGB) > 12 g/dL for females or > 13g/dL for males
- White Blood Cell Count (WBC) > 3,000 mm3
- Neutrophils > 1,500 mm3
- Platelets > 80,000 mm3
Chemistry laboratory results of:
- Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and direct bilirubin
- Antinuclear antibody (ANA) < 1:320
- Fasting Glucose 70-140 mg/dL Note: If glucose levels are between 116-140 mg/dL or an individual has diabetes, HbA1C must be < 8.5

EXCLUSION CRITERIA:

Previous hepatitis C treatment
Pregnant women or partners of pregnant women
Patients or partners of patients who intend to become pregnant any time during the 48 weeks
Women who are breast feeding
People with liver disease not caused by hepatitis C
Individuals infected with the hepatitis B virus and/or human immunodeficiency virus (HIV)
Patients with a history of liver cancer (hepatocellular carcinoma)
Known blood disorders such as hemoglobinopathy, coagulopathy, or G6PD deficiency
Body organ transplant
Any known or suspected cancer within the past 5 years
Individuals who currently use EPO, G-CSF and/or GM-CSF
Those having a history of or active clinical gout
People who have chronic pulmonary disease
Individuals who have a medical condition that would likely require systemic steroids
Those with a history of central nervous system (CNS trauma) or seizure disorders
Current or previous use of lithium or antipsychotic drugs
Individuals who currently have or show signs of moderate to severe depression
Patients with clinically significant electrocardiogram (ECG) abnormalities
Individuals with serious heart problems such as those who have had a heart attack, high blood pressure, or other heart problems
Patients that weigh > 231-275 pounds (105-125 kg) AND have a body mass index (BMI) > 30 AND have 3 or more of the risk factors below: (a) Strong family history of coronary heart disease (CHD) which includes 2 or more first-degree relatives with CHD or family history of early CHD at age < 55 for male relatives or < 65 for female relatives (b) People with abnormal total cholesterol and/or sub fractions (uncontrolled hypercholesterolemia) (c) Diabetes (d) Hypertension (e) Smoking

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00081770

Sponsors and Collaborators

Schering-Plough

Investigators

Study Director:

Stephanie S Noviello, MD

Schering-Plough

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided by Schering-Plough

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug 6;361(6):580-93. Epub 2009 Jul 22.

Responsible Party:	Schering-Plough ( Janice Albrecht, PhD - Vice President, Global Clinical Research, Hepatology )
Study ID Numbers:	P03471, 2552898
Study First Received:	April 20, 2004
Last Updated:	December 20, 2007
ClinicalTrials.gov Identifier:	NCT00081770 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Antimetabolites
Interferon-alpha
Anti-Infective Agents
Liver Diseases
Hepatitis, Chronic
Interferons
Ribavirin
Hepatitis, Viral, Human
Angiogenesis Inhibitors
Antiviral Agents

Hepatitis
Virus Diseases
Digestive System Diseases
Peginterferon alfa-2b
Peginterferon alfa-2a
Hepatitis C
Interferon Alfa-2a
Hepatitis C, Chronic
Interferon Alfa-2b

Additional relevant MeSH terms:

Antimetabolites
Anti-Infective Agents
Liver Diseases
Flaviviridae Infections
Hepatitis, Chronic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Ribavirin
Physiological Effects of Drugs
Hepatitis, Viral, Human
Therapeutic Uses
Growth Inhibitors
Hepatitis C

Angiogenesis Modulating Agents
RNA Virus Infections
Growth Substances
Antiviral Agents
Angiogenesis Inhibitors
Pharmacologic Actions
Virus Diseases
Hepatitis
Digestive System Diseases
Peginterferon alfa-2b
Peginterferon alfa-2a
Hepatitis C, Chronic
Interferon Alfa-2b

ClinicalTrials.gov processed this record on September 10, 2009